Artificial city

new beneficial bihormonal artificial pancreas after pancreatectomy | Health, Medicine and Fitness

Physician Information Staff

FRIDAY, Sept. 9, 2022 (HealthDay News) — Patients after total pancreatectomy receiving a new fully closed-loop bihormonal artificial pancreas (BIHAP) using both insulin and glucagon, spend significantly longer in euglycemia than those currently receiving diabetes care, according to a study published online September 7 in JAMA surgery.

Charlotte L. van Veldhuisen, MD, of the University of Amsterdam, and colleagues examined the efficacy and safety of BIHAP in patients after total pancreatectomy in a randomized crossover clinical trial. Twelve adult outpatients after total pancreatectomy were randomly assigned to fully closed-loop BIHAP for seven days, followed by seven days of current diabetes care (insulin pump or pen therapy) or the same treatments in order reverse ; three patients did not complete the BIHAP phase and one was replaced.

The researchers found that compared to current diabetes care, time spent in euglycemia (70–180 mg/dL) was significantly higher during BIHAP treatment (median, 78.30 vs. 57.38%). Time spent in hypoglycemia was lower with BIHAP than with current care (median, 0.00 versus 1.61%). No serious adverse events were reported.

People also read…

“Larger randomized studies with a longer treatment period are needed to substantiate the use and feasibility of BIHAP for the treatment of diabetes in patients after radical pancreatectomy, with sufficient attention to patient-reported outcomes, such as quality of life,” the authors write.

Several authors disclosed financial ties to pharmaceutical and medical device companies, including Inreda Diabetic, which provided the BIHAP systems used in the study.

Abstract/Full text (subscription or payment may be required)

Editorial (subscription or payment may be required)